Description: Segment 1 Over images of laboratory work and equipment, a voiceover explains how the introduction of a new pharmaceutical item onto the market takes much time and effort and now it normally takes years for the process to be complete. She then goes on to talk about how in September 1986 a double blind clinical study to evaluate the drug Retrovir was stopped because it was obvious it helped in stopping mortality in patients. Production of the drug became a priority for Wellcome. Barry Alcock, in charge of Primary Manufacturing at the Dartford plant, describes how the plant was adapted to cope with the new product. Dave Lemon in the Tablet Manufacturing department describes how capsule making equipment was brought in very quickly. Time start: 00:00:00:00 Time end: 00:03:59:04 Length: 00:03:59:04 Segment 2 Due to the urgency placed on immediate manufacturing of Retrovir, production of capsules went ahead immediately. Doug Faulkner from the Quality Assurance department explains how the first batch had to meet standards, and pass 300 analyses. Jeff Waddingham, the Retrovir Supplies Coordinator, describes how orders were processed immediately, how package design could be adapted for different coountries and how distribution to different countries worked. The voiceover explains how usually, a new drug being put onto the market takes about three years, but Retrovir took just six months. All the previously seen Wellcome staff discuss what a challenge this process was and how proud they are to have completed it in time. A note from the Wellcome Trust is shown at the end thanking all the staff who made the introduction of Retrovir a success. Time start: 00:03:59:04 Time end: 00:07:26:24 Length: 00:03:27:19